Liver cancer surgery: long-term outcomes by tumor size
Part of Cancer, Digestive system clinical trials.
This study looks at people with a single liver cancer tumor that can be removed by surgery. It checks how tumor size (especially larger than 6.5 cm) and signs of tumor invasion into blood vessels affect long-term outcomes over 10 years.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a single liver cancer tumor that can be removed with surgery.
- Your cancer must be at an early stage (pT1N0M0 or pT2N0M0), meaning it hasn't spread to lymph nodes or other organs.
- Your tumor size must be known (the study looks at how size affects outcomes).
- Your medical records must have accurate dates for survival and whether the cancer returned.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two treatments—radiation (SBRT) and surgery—for people with a small liver tumor (≤5 cm) that hasn't spread. The goal is to see which treatment works better.
This study uses digital scans of your tumor tissue and CT/MRI images to build a computer model that helps predict whether you might need extra treatment (adjuvant therapy) after liver cancer surgery. The goal is to use your own tissue and scan data to personalize follow-up care.
This study examines medical records from patients who received a liver transplant for hepatocellular carcinoma (a type of liver cancer) between 2018 and 2023. The goal is to understand treatment outcomes and improve care for future patients.
This trial looks at whether people with an initially untreatable liver cancer that has shrunk or disappeared after drug therapy should have surgery or just continue monitoring. It aims to see which approach helps people live longer.
This study looks at genetic markers in the blood of people with liver cancer who are having surgery, either right away or after some treatment first. It aims to find out why some patients do better, which could help personalize care.
This trial is studying people with liver cancer (hepatocarcinoma) whose cancer returns (recurs) or never fully goes away (persists) after surgery. It looks at patterns after treatment at a specific study center, which may help guide better care for future patients.
Hear when a new Hepatocellular Carcinoma (HCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.